CA2207216A1 - System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells - Google Patents
System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cellsInfo
- Publication number
- CA2207216A1 CA2207216A1 CA002207216A CA2207216A CA2207216A1 CA 2207216 A1 CA2207216 A1 CA 2207216A1 CA 002207216 A CA002207216 A CA 002207216A CA 2207216 A CA2207216 A CA 2207216A CA 2207216 A1 CA2207216 A1 CA 2207216A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- human
- mouse
- bone marrow
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000012010 growth Effects 0.000 title claims description 17
- 230000004069 differentiation Effects 0.000 title description 15
- 210000002798 bone marrow cell Anatomy 0.000 title description 9
- 238000012423 maintenance Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 151
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 72
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 72
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 49
- 241000699670 Mus sp. Species 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 36
- 108090000695 Cytokines Proteins 0.000 claims abstract description 34
- 102000004127 Cytokines Human genes 0.000 claims abstract description 33
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims abstract description 28
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 claims abstract description 21
- 238000010171 animal model Methods 0.000 claims abstract description 20
- 238000001415 gene therapy Methods 0.000 claims abstract description 11
- 230000011132 hemopoiesis Effects 0.000 claims abstract description 8
- 238000010253 intravenous injection Methods 0.000 claims abstract description 4
- 210000000130 stem cell Anatomy 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 238000011579 SCID mouse model Methods 0.000 claims description 23
- 241000283984 Rodentia Species 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 230000005855 radiation Effects 0.000 claims description 12
- 231100000518 lethal Toxicity 0.000 claims description 8
- 230000001665 lethal effect Effects 0.000 claims description 8
- 231100001160 nonlethal Toxicity 0.000 claims description 7
- 230000004083 survival effect Effects 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 238000010998 test method Methods 0.000 claims description 3
- 101710128836 Large T antigen Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 abstract description 27
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract description 12
- 210000002536 stromal cell Anatomy 0.000 abstract description 10
- 238000007912 intraperitoneal administration Methods 0.000 abstract description 7
- 230000010261 cell growth Effects 0.000 abstract description 6
- 108020004707 nucleic acids Proteins 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 33
- 150000007523 nucleic acids Chemical class 0.000 description 33
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 12
- 230000036436 anti-hiv Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 102100034343 Integrase Human genes 0.000 description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 7
- 230000003394 haemopoietic effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000005757 colony formation Effects 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- -1 additional SCF Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 102000052611 human IL6 Human genes 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 208000008852 Hyperoxaluria Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000002791 cfu-m Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037998 chronic venous disease Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004148 metal metabolism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000242 supportive cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method of engrafting human or non-human primate pluripotent stem cells, such as CD34+ cells, in a mouse. The method comprises administering to irradiated mice immortalized human or non-human primate bone marrow stromal cells which express cytokines supporting growth of cells, such as CD34+ cells, and, sequentially or simultaneously, administering purified human or non-human primate CD34+ cells. The stromal cells and CD34+ cells can be administered by intraperitoneal or intravenous injections. The invention can be used to evaluate gene therapy protocols for human CD34+ cells as well as having applications in the treatment of patients exposed to irradiation such as during a bone marrow transplant. The invention also provides an animal model for the study of human hematopoiesis.
Description
W O96117627 PCTAUS9~lSg86 SYSTEM FOR THE MAINTENANCE, GROWTH AND DIFFERENTIATION
OF HUMAN AND NON-HUMAN PRIMATE PLURIPOTENT STEM, PROGENITOR AND MATURE BONE MARROW CELLS
SPECIFICATION
Backqround of the Invention Field of the Invention The present invention relates to the use of an immortalized human cell line to create a human microenvironment in mice for the study of human disease states. In this human microenvironment, cells such as human and non-human primate pluripotent stem cells can be maintained and differentiated. In particular, the present invention relates to the injection of an immortalized human stromal cell line (such as Lof(11-10)) into mice to create a human microenvironment supplying human cytokines that are necessary to support the engraftment, maintenance and differentiation o~ human and non-human primate CD34+ stem cells. Such a hllm~n microenvironment provides a valuable animal model for the study of human hematopoiesis.
Description of the Prior Art Biomedical research relies heavily on ~n;m~l models to gain an underst~n~ng of the various disease states in human.
Using animal models, researchers hope to gain an understanding of disease states which will enable them to intervene in the disease process. Animal models have been successfully used to study a range of human diseases, everything from the safety of aspirin and metal metabolism to bacterial and viral infections. For example, mice have been used to investigate Alzheimer's disease (Wi et al., Chunq Kuo Chunq Hsi I Chieh Ho Tsa Chih (China) 12:622, 1992), staphylococcal infection (Bel'skii et al., Zh. Mikrobiol EPidemiol. Immunobiol. (USSR) 3:16, 1989), encephalopathy (Ross et al., Neurotoxicoloqy 9:581, 1988), ankylosis W O96/17627 PCTrUS95115986 (Mahowald et al., Arthritis Rheum. 31:1390, 1988), autoimmunity (Roberts et al., J. Com~. Pathol. (Enqland) 100:391, 1989), systemic lupus (Mendlovic et al., Proc. Natl.
Acad. Sci. USA 85:2260, 1988), epilepsy (King et al., EPilePsia 30:257, 1989), insulin-dependent diabetes (Gottlieb et al., Diabetes Care 11:29, 1988), connective tissue disease (Rosenberg N.L., Arthritis Rheum. 31:806, 1988~, and copper metabolism (Shiraishi et al., Biol. Neonate (Switzerland) 54:173, 1988). Rats have also served as successfully ~n~m~l models for studying cystic fibrosis (Hunsinger et al., Med.
HYpotheses (Enqland) 28:81, 1989), osteoporosis (Yamazaki et al., J. Bone Miner Res. 4:13, 1989), and obesity and hypertension (Crandall et al., J. AP~l. Physiol. 64:1094, 1988).
Animal species other than rodents have also been used successfully to study human diseases. Pigs have been used to investigate E. coli infection (Sarmiento et al., Am. J. Vet.
Rçs. 49:1154, 1988), acetaminophen (Henne-Bruns et al., Res.
Ex~. Med. (GermanY) 188:463, 1988), asthma (Karol M.H., Bull.
Eur. PhysioPathol. Respir. (Enqland) 23:571, 1987), and herpes virus infection (Hsiung et al., Antiviral Res.
(Netherlands) 12:239, 1989), while sheep have been employed to study periodontitis (Ismaiel et al., J. Periodontol.
60:279, 1989) and chronic venous disease (Jessup et al., J.
Vasc. Surq. 8:569, 1988). Chronic subluxation (De Boer et al., J. ManiPulative PhYsiol. Ther. 11:366, 1988) and respiratory distress syndrome (Lachmann B., Dev. Pharmacol.
Ther. (Switzerland) 13:164, 1989) have been studied in adult and fetal rabbits, while hyperoxaluria (Danpure et al., J.
Inherit. Metab. Dis. (Netherlands) 12:403, 1989) has been studied in felines. Arthritis has been studied in both rats (Barthold et al., Ann. NY Acad. Sci. 539:264, 1988) and rhesus monkeys (Pritzker et al., PR Health Sci. J. (Puerto Rico) 8:99, 1989). HIV infection has been intensively studied using such animal models as chimpanzees, gibbons, mice, rabbits, baboons, and rhesus monkeys ~Spertzel R.O., Antiviral Res. (Netherlands) 12:223, 1987).
r Where suitable animal models are not available, however, the study of the disease, and its treatment, may be severely hampered. In particular, the study of hl~m~n hematopoiesis has been hampered by the lack of an animal model for studying hematopoietic cells. The lack of a suitable animal model is especially keen today with the emergence of gene therapy for hllm~n diseases. Presently, the only available means of evaluating a given gene therapy is a clinical trial - a costly, complex and time-consuming endeavor. Accordingly, an ~ni ~1 model for studying the introduction of genetic material into the human pluripotent stem cell would be a major advance for the field.
Hematopoiesis, the formation of mature blood cells, involves a complex scheme of multilineage differentiation (Metcalf, Nature 339:27-30, 1989). In the bone marrow, pluripotent stem cells proliferate and differentiate into progenitor cells which then develop into different types of mature blood cells (Gordon et al., Bone Marrow Trans~lant 4:335, 1989; Dexter et al., Ann. Rev. Cell Bio. 3:423, 1987).
Indeed, the pluripotent stem cell, identified by the presence of the CD34 hematopoietic cell surface antigen, is capable of differentiating and giving rise to cells of all hematopoietic lineages (Sprangruide et al., Science 241:58, 1988).
Two animal models, based on the severe combined immunodeficiency (SCID) mouse, have been developed to study the growth and differentiation of human bone marrow cells, the source of hematopoietic cells. Both of these models, however, have drawbacks and disadvantages which limit their usefulness. In the first system, established by John Dick, human cytokines are supplied by systemic administration to the SCID mice transplanted with human bone marrow (Lapidot et al., Science 255:1137-1141 (1992)). (See also, Dick et al., Sem. Immunol. 3:367-378 (1991).) This system is very expensive, re~uiring 3-times a week injections of purified recombinant cytokines.
The second system, developed by Jim McCune, involves the surgical implantation of human fetal tissues into SCID mice W O 96tl7627 PCTrUS95/lS986 (McCune et al., Science 241:1632-1639 (1988); and Kaneshima et al., Nature 348:561-562 (1990)). In the McCune system, human fetal liver, human fetal thymus and/or human fetal lymph nodes are implanted into SCID mice. These mice support the differentiation of mature human T cells and B cells. The McCune system has also succeeded in sustaining active human hematopoiesis in SCID mice implanted with human fetal bone (Kyoizumi et al., Blood 79:1704-1711 (1992)). The surgical procedures, however, which must be conducted on each mouse with the McCune system are time consuming and costly. In addition, the availability of fetal tissue is limited and its use makes this approach controversial.
SUMMARY OF THE INVENTION
Accordingly, it is one object of the present invention to provide an animal model that can be used as a pre-clinical assay to evaluate different proposed gene therapies by testing whether the therapy effectively corrects the given deficiency.
It is a further object of the present invention to provide an inexpensive, straight forward, and versatile means of studying the growth and differentiation of human bone marrow cells.
It is another object of the present invention to provide a human microenvironment in mice using an immortalized human cell line.
Various other objects and advantages of the present invention will be apparent from the drawings and the following description of the invention.
To accomplish these objectives, the present invention relates to a method of engrafting human or non-human primate stem cells in a mouse to create an animal model useful for the study of hematopoietic cells. In one embodiment, the cells are primitive stem cells that have the capability of differentiating into all hematopoietic cells. In a preferred embodiment, the stem cells are CD34+. In a particular embodiment, the method comprises irradiating the mouse with a CA 022072l6 l997-06-06 W 096/17627 PCTAUS95/lSg86 lethal or non-lethal dose of radiation; administering to the irradiated mouse immortalized human or non-hllm~n primate bone marrow stromal cells which express cytokines supporting growth of stem cells; and administering to the irradiated mouse purified human or non-human primate stem cells.
In another embodiment, the present invention relates to a method of testing the effectiveness of a gene therapy protocol against an infectious agent such as HIV. The method comprises irradiating a first and a second mouse with a lethal or non-lethal dose of radiation; administering to the irradiated mice immortalized human or non-human primate bone marrow stromal cells which express cytokines supporting growth of CD34+ stem cells; introducing a proposed therapeutic gene segment into a first group of human CD34+
stem cells; purifying the cells from the first group of CD34+
stem cells expressing the gene segment; introducing a control gene segment into a second group of human CD34+ stem cells;
administering the purified CD34+ stem cells expressing the gene segment to the first irradiated mouse and administering the control cells to the second irradiated mouse; challenging both irradiated mice with the retrovirus; and comparing the survival of the hllm~n CD34+ stem cells from the two mice.
In a further embodiment, the present invention relates to an animal model for the study of human hematopoiesis. This model comprises a rodent into which human or non-human primate CD34+ stem cells have been engrafted in the present of immortalized hllm~n or non-human primate bone marrow stromal cells. In a preferred embodiment, the rodent is a mouse, such as a SCID mouse.
BRIEF DESCRIPTION OF THE DRAWINGS
d Figure 1 shows the relative expression of cytokine mRNA
transcripts in the human stromal cell line Lof(l1-10)~
Figure 2 shows the survival of lethally irradiated SCID
mice reconstituted with the human stromal cell line Lof(11-10) .
W O96/17627 PCTrUS95/15986 Figure 3 shows the detection of Lof~ 10) cells in SCID
mice by DNA polymerase chain reaction (PCR).
Figure 4 shows the detection of human and monkey CD34 derived cells in the bone marrow compartment of SCID mice by reverse transcriptase (RT)-dependent RNA PCR. Lanes 1-4 show mice receiving 1 x 10 Lof(11-10) cells by intraperitoneal injection (i.p.) plus 3 x 105 human CD34+ cells by intravenous injection (i.v.) Lane 5 shows mice receiving 1 x 107 Lof(11-10) cells i.v. plus 2 x 105 monkey CD34+ cells i.v. Lanes 6-8 show mice receiving 1 x 10 Lof(11-10) cells i.p. plus 2 x 10 monkey CD34+ cells i.v.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method of engrafting human or non-human primate pluripotent stem cells in a rodent. Using severe combined immunodeficiency (SCID) mice, the inventors developed a method for engrafting human or non-human primate pluripotent CD34+ stem cells into the SCID
mouse. Although mice were utilized in the development of the present method, any rodent may be used. Preferred rodents include SCID mice; these mice have mutated scid genes which prevent production of mature T cells and B cells by the mice.
All other hematopoietic lineages are produced as normal in these mice.
Pluripotent stem cells can be defined functionally as well as phenotypically. Functionally, pluripotent stem cells are those hematopoietic cells having the capability of multilineage differentiation and self-renewal. Pluripotent stem cells can also be defined phenotypically by cell sur~ace markers. For example, human stem cells have been characterized as CD34+ CD38-, HLA-DR-, THY+, and Rhl23-.
In the present method, human and non-human primate pluripotent stem cells are engrafted in a rodent, preferably a mouse. To engraft human and non-human primate stem cells so that the cells are maintained and differentiated in the mouse, the mouse is first irradiated with a lethal or non-lethal dose of radiation. For example, each mouse can be exposed to 200 or 400 rads o~ gamma irradiation. Once irradiated, the mice are given a dose of immortalized cells which support the growth of stem cells. In one embodiment, the supportive cells are immortalized bone marrow stem cells which express cytokines. Finally, the mice are given an injection of purified hl~m~n or non-human primate CD34+ cells.
The cells engrafted into the rodent are preferably CD34+
stem cells obtainable from bone marrow, peripheral blood or cord blood. These cells can be isolated from human or non-human primate bone marrow or blood using methods known in the art. Other cells useful in this engraftment method include, but are not limited to, fetal liver and fetal thymus.
Immortalized bone marrow stromal cells are administered to the irradiated mice to provide, within the mice, a substratum on which later administered primitive hematopoietic cells, such as CD34+ stem cells, can adhere.
These stromal cells also nurture such cells by producing the cytokines necessary for their growth and differentiation.
The immortalized bone marrow stromal cells serve as a microenvironment within the mouse where stem cells engraftment, differentiation, and self-renewal can occur.
The immortalized stromal cells preferably produce human cytokines. Suitable immortalized bone marrow stromal cells include, but are not limited to, the Lof(11-10) cell line.
The Lof(11-10) cell line is preferred because these cells naturally produce human cytokines and, therefore, can support the growth of CD34+ cells in vitro. The Lof(11-10) cell line produces Il-1~, IL-1~, IL-6, IL-8, GM-CSF, M-CSF, G-CSF, and SCF (stem cell factor). In addition, these cells are immortalized using the SV40 large T-cell antigen and, unlike transformed cells, do not produce tumors when administered to mlce .
Like the Lof(11-10) cell line, the immortalized bone marrow stem cells employed in the present invention may naturally produce the desired cytokines. Alternatively, the bone marrow stem cells can be genetically engineered, using standard methods known in the art, to produce the desired _ _ _ _ _ _ _ _ _ _ _ _ _ . . . . . .
W O 96/17627 PCTnUS95/15986 cytokines or other desired supporting components. For example, the Lof(ll-lO) cell could be modified to further produce such human cytokines as IL-3, additional SCF, IL-7 or IL-2.
The immortalized bone marrow stromal cells and the purified CD34+ cells are administered in amounts sufficient to promote engraftment of the CD34+ cells. Preferably, 0.1-5.0 x 107 bone marrow stromal cells are administered to each rodent, more preferably each rodent is given 0..1, 0.5, 1.0 or 5.0 x 10 cells. Preferably, 0.1 - 5.0 x 105 CD34+ cells are given to each rodent. More preferably, each rodent is given a dosage of 0.1, 0.5, 1.0 or 5.0 x 105 CD34+ cells.
These two populations of cells can be administered to the mouse simultaneously or sequentially. Preferably, the immortalized bone marrow stromal cells are administered first intraperitoneally (i.p.), followed by sequential administration of the purified CD34+ cells intravenously (i.v.). For example, the purified CD34+ cells can be administered about 10 days after the immortalized bone marrow stromal cells are administered, preferably 2-7 days after the immortalized bone marrow stromal cells are A~m; nl stered.
The present invention is an inexpensive, straight forward, and versatile system for engrafting human and non-human primate CD34+ cells in the mouse animal model. The method is relatively inexpensive as the immortalized bone marrow stromal cells are capable of growth in cell cultures.
For example, ~of(11-10) cells can be grown to 1 x 10 per T225 flask, which is enough cells to introduce into one mouse. The method is straight forward in that the injection of the immortalized bone marrow stromal cells is easy to perform and provides a continuous supply of human cytokines in the mouse. Finally, the method is versatile. The immortalized bone marrow stromal cells can be made to express additional htlmAn growth factor, surface receptors and/or cytokine genes.
Mice engrafted with human stem cells such as CD34+ cells, according to the present invention, produce all lineages of W 096117627 PCTAUS95/15g86 hllm~n blood cells. The engrafted CD34+ cells are able to proliferate and differentiate into all blood cell lineages including human T cells and human B cells, thereby establishing a htlm~n hematopoietic microenvironment in the mouse. This animal model for human hematopoiesis has several uses. For example, the mice of the present invention can be used as a model for studying infectious diseases in vivo.
This model can also be used to screen compounds for antiviral activity in vivo. This mouse model can also be used to assay for hematopoietic growth factors, immune modulators and/or immune toxins. Finally, mice engrafted with human CD34+
cells can be used in the production of human monoclonal antibodies and hl~m~n cytolytic T cell clones.
The present invention also relates to a method of testing the effectiveness of gene therapy protocols against infectious agents such as human immunodeficient virus (HIV), human cytomegalovirus (CMV), human papilloma virus (HPV), and Epstein-Barr virus ~EBV). In this testing method, putative therapeutic genetic material is introduced into the human CD34+ cell and the CD34+ cells are then engrafted in a rodent to determine whether the introduction of the genetic material prolongs the survival of the CD34+ cells and their progeny in vivo. The genetically engineered CD34+ cells are engrafted in, for example, a mouse as described above. The mouse is then challenged with the infectious agent and survival of the human CD34+ cells and their progeny is determined.
For example, the present testing method can be used to determine the effectiveness of a gene therapy protocol against HIV, the causative agent of AIDS. An effective gene therapy protocol against HIV infection would confer resistance against HIV to cells in vivo. If resistance to HIV infection can be conferred upon cells in vivo using a - particular gene therapy protocol, further studies would be warranted to optimize the therapeutic benefits of the molecular intervention in AIDS patients.
In the method of the invention, a proposed anti-HIV gene is introduced into human CD34+ cells and the cells expressing W O96tl7627 PCTrUS95/15986 the gene are then purified. Introduction of the proposed anti-HIV gene into CD34+ cells can be accomplished by techniques standard in the art such as a viral-mediated vector system. Purification of the expressing CD34+ cells can be easily done by techniques in the art such as either drug selection or surface expression of genes co-introduced with the anti-HIV gene. A control gene is introduced into a separate aliquot of human CD34+ cells. The control gene, for example, contains the proposed anti-HIV gene but has a frameshift which abrogates expression of the proposed anti-HIV gene.
Effects of the proposed anti-HIV gene and the control anti-HIV gene can be analyzed using either one or two populations of mice that have been irradiated with a lethal or non-lethal dose of radiation and given a dose of immortalized human bone marrow stromal cells which express cytokines supporting the growth of CD34+ cells. If two mice populations are used, one population is administered the human CD34+ cells expressing the proposed anti-HIV gene and the other is given the human CD34+ control cells. The mice are then challenged with HIV. The half-life and survival of the human CD34+ cells and their progeny which express the proposed anti-HIV gene are compared with the CD34+ control cells. These two populations can be distinguished using techniques familiar in the art such as a limited dilution PCR
of cells derived from the spleen and bone marrow with primers specific for each vector. In this way, the number of cells which persist can be determined as a function of time, and the half-life of cells transduced with each vector can be assessed.
The present system can also be used to assay for the ' successful introduction of a therapeutic gene into the true stem cells, which are capable of self-renewal and life-long expression. This can be determined by PCR analyses of human spleen colonies growing in SCIDs 14 days after CD34+ cells injection. These colonies represent the earliest assayable cells derived from the pluripotent stem cell. Introduction W O 96/17627 ~CT~US95J15g86 of an effective therapeutic into this cell population would ensure a one-time gene therapy in recipient patients.
This is important because only 0.1 to 1 percent of the CD34+ cells are true pluripotent stem cells; the rem~;n;ng 99 percent of the CD34+ cells are committed progenitors which will give raise to various blood lineages. Thus, the expression of a therapeutic gene in the CD34+ population does not necessarily mean that the therapeutic is in the stem cell. Although the expression of a therapeutic would be useful in the mature cells in the blood, the life-span of these mature cells is finite. Introduction of the therapeutic into the pluripotent self-renewing stem cell insures a continuous supply of committed progenitors which in turn insures a continuous supply of mature cells in the blood armed with the therapeutic.
By way of example, in the case of HIV, the anti-HIV gene would be present in the mature T cells and monocytic cells of an HIV in~ected patient, potentially allowing that individual to lead a normal life in spite of harboring the AIDS virus.
At the present time, a functional assay ~or the introduction of a therapeutic into the stem cell is nonexistent and would have to wait for the outcome of a clinical trial or a bone marrow transplant in primates. The use of the spleen colony assay of the present invention for human cells within the SCID spleen would greatly facilitate the development of the procedures to assay for the introduction of the therapeutic gene into human stem cells, insuring the continuous supply of committed progenitors and mature cells armed with the antiviral gene.
The present invention further relates to a method of treating patients exposed to radiation to reduce recovery time. Radiation is currently used to treat different forms of cancer including leukemia and to treat patients undergoing bone marrow transplantations. When patients are exposed to radiation for bone marrow transplants, all of their bone marrow is destroyed, including their progenitor cells (which give rise to the mature cells in the blood) and the stromal =
W O96/17627 PCTrUS95115986 cells (which nurture the stem and progenitor cells to renew, grow and differentiate). The window of time (1 to 2 months) between whole body irradiation and the growth/differentiation of the "newly" introduced bone marrow cells into the patient is the most critical time in bone marrow transplantation.
This is the time when the patient is most susceptible to either rejection (host versus graft disease) or opportunistic infections (due to an incompetent immune system).
Cytokine therapy has shown promise when used during the period of time between whole body irradiation and growth/
differentiation of the new cells, suggesting that the establishment of a functional stromal layer is essential to supply the cytokines needed to allow stem and progenitor cell growth. The "newly" introduced bone marrow cells will, in time, establish their own stromal layer; however, the introduction of a stromal cell line expanded in vitro and introduced with the "new" marrow may reduce this window of uncertainty. The stromal cells can be obtained from the patients' own marrow or from their donor by procedures similar to those used to establish the Lof(ll-10) cell line.
For the purposes of illustrating a preferred embodiment of the present invention, in the following non-limiting examples, the immortalized human stromal cell line Lof(ll-10) was used to reconstitute SCID mice with human and monkey CD34+ cells. It is, however, to be understood that the discussion generally applies to the reconstitution of any mouse with human cells capable of producing cytokines.
- EXAMPLES
Example 1: Lof(11-10) Cells Produce Cytokines Which Su~ort In Vi tro CD34+ Cell Growth Lof(11-10) is a hllm~n immortalized stromal cell line established from hllm~n bone marrow by transfection of a plasmid containing a SV40 large T antigen (pSV3gt) as described by S.W. Gartner (Establishment and Characterization of Human Bone Marrow Stroma-Derived Cell Lines Transformed Following Transfection with Cloned SV40 Early Region DNA
(1984) (Ph.D. dissertation, Stanford University). To determine whether Lof(ll-lO) cells produce cytokines which are required to support cell growth, Lof(ll-10) cells were grown in T162 tissue culture flasks for 10 days. The expression of cytokine mRNA transcripts in the hof(ll-10) cultures was then detected using reverse transcriptase (RT)-dependent RNA PCR analysis.
Briefly, total RNA was isolated from the cultured Lof(11-10) cells using the RNAzol B RNA isolation solvent (Tel-Test) according to manufacturer's instructions. Ten micrograms of purified RNA were incubated at 37~ C for 30 minutes with 100 units of RNase-free DNase in 0.1 M sodium acetate, 5 mM MgC12 in a 50 ~l reaction, followed by phenol/chloroform extraction and ethanol precipitation. Samples of 5 ~g of DNase-treated RNA were converted to cDNA by primer extension with 0.1 mg/ml random primers, and 600 units of Moloney murine leukemia virus RT (Bethesda Research Laboratories).
The RNA and the random primers were heated to 70~ C for 10 minutes followed by quick cooling on ice. The mixture was then incubated for 1 hour at 37~ C in a 40 ~l reaction volume containing 50 mM Tris-HCl (pH 8.3), 40 mM KCl, 6 mM
MgCl2, 10 mM DTT and 750 ~M dNTPs. The RT reaction was terminated by heating at 90~ C for 5 minutes before PCR
amplification.
Aliquots of the DNase-treated RNA, with and without conversion to cDNA by reverse transcriptase, were amplified with 0.5 ~M sequence specific primer pairs in a 50 ~l W O 96/17627 PCTrUS95/15986 reaction volume containing 2 ~1 of reverse-transcribed cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgC12, 200 mM dNTPs, and 1.5 units of Taq DNA polymerase (Perkin-Elmer/Cetus) for 28 cycles. The specific primer pairs used were as follows:
I~-1~: 5'-ATGGCCAAAGTTCCAGACATGTTTG (SEQ ID N0:1) 3'-GGTTTTCCAGTATCTGAAAGTCAGT (SEQ ID N0:2) IL-l~: 5'-ATGGCAGAAGTACCTAAGCTCGC (SEQ ID NO:3) 3'-ACACAAATTGCATGGTGAAGTCAGTT (SEQ ID N0:4) IL-6: 5'-ATGAACTCCTTCTCCACAAGCGC (SEQ ID N0:5) 3'-GAAGAGCCCTCAGGCTGGACTG (SEQ ID NO:6) IL-8: 5'-ATGACTTCCAAGCTGGCCGTGCT (SEQ ID N0:7) 3'-TCTCAGCCCTCTTCAAAAACTTCTC (SEQ ID NO:8) GM-CSF: 5'-ATGTGGCTGCAGAGCCTGCTGC (SEQ ID N0:9) 3'-CTGGCTCCCAGCAGTCAAAGGG (SEQ ID N0:10) G-CSF: 5'-GAGTGTGCCACCTACAAGCTGTGCC (SEQ ID N0:11) 3'-CCTGGGTGGGCTGCAGGGCAGGGGC (SEQ ID N0:12) M-CSF: 5'-GAGGAGGTGTCGGAGTACTGTAGCCACATG (SEQ ID N0:13) 3'-CATAGAAAGTTCGGACGCAGGCCTTGTCATG (SEQ ID NO:14) TGF~: 5'-ATGGTCCCCTCGGCTGGACAG (SEQ ID N0:15) 3'-GGCCTGCTTCTTCTGGCTGGCA (SEQ ID N0:16) SCF: 5'-CCACTGTTTGTGCTGGATCGCAGCGCTGCC (SEQ ID N0:17) 3'-GTCATCCACTATATTCACAAGTTTGTCTATG (SEQ ID N0:18).
The PCR profile consisted of 94~ C for 1 minute, 60~ C for 1 minute, and 72~ C for 3 minutes, for the denaturation, annealing, and extension reactions, respectively. The samples were incubated at 94~ C for 3 minutes before the start of the PCR profile and a final extension time of 20 minutes at 72~ C was provided after the 28th PCR cycle.
The amplified products were separated on 1.2~ agarose gels in the presence of 0.5 ~g/ml ethidium bromide, transferred to nylon membrane, and probed with 32p end-WO 96117627 PCT~US9~ i98C
labeled oligodeoxyribonucleotides having the following sequences:
IL~ CCTTCTATCATGTAAGCTATGGCCCACTCC (SEQ ID NO:19) IL-1~: GGTCCATATGAACTGAAAGCTCTCCACCTC (SEQ ID NO:20) IL-6: GAAAAAGATGGATGCTTCCAATCTGG (SEQ ID NO:21) IL-8: GAACTGAGAGTGATTGAGAGTGGACCACAC (SEQ ID NO:22) GM-CSF: CGCCTGGAGCTGTACAAGCAGGGCCTGCGG (SEQ ID NO:23) G-CSF: CTGCAGGCCCTGGAAGGGATCTCCCCCGAG (SEQ ID NO:24) M-CSF: GAGGACACCATGCGCTTCAGAGATAACACC (SEQ ID NO:25) TGF~: GGAACCTGCAG~lllllGGTGCAGGAGGAC (SEQ ID NO:26) SCF: CCAAAAGACTACATGATAACCCTCAAATATG (SEQ ID NO:27).
The probe sequences represented regions internal to, and not overlapping with, primers used for amplification.
Hybridization signals were quantified directly from the nylon membrane using a PhosphorImager sc~nner with ImageQuant software form Molecular Dynamics (Sunnyvale, CA).
The results, shown in Figure 1, demonstrate that Lof(11-10) cells produce cytokines, such as IL-lB, IL-8, M-CSF and B-ACTIN, which support the growth of cells, such as the CD34+
stem cell. Additional cytokines with short-lived mRNAs like Il-6, GM-CSF, and G-CSF are also expressed in the present of protein synthesis inhibitors.
Cytokine expression by Lof(11-10) cells, 5637 cells (a human bladder primary carcinoma) and GCT cells (a human fibrous histicytoma) were quantitated using ELISA
immunoassays. The 5637 and GCT cell lines are available from American Type Culture Collection (ATCC), Rockville, MD.
Briefly, measurement of cytokines was performed with culture supernatant using ELISA kits from R & D Systems (Minneapolis, MN) according to the manufacturer's specifications. The results of the ELISA are shown below in Table 1.
W O 96/17627 PCTrUS95/15986 CYtokines (Pq/ml ) Condition Media IL-~ IL-6 GM-CSFSCF
GCT 115 ,300 ~500~10 5637 ~250 ~300 ~500250 Lof(11-10) 200 3665 150 70 Example 2: Lof(11-10) Cells SuPPort In Vitro CD34+
Proqenitor Cells Initially, attempts were made to establish a stroma-dependent long-term bone marrow culture using the Lof(11-10) cells as a stromal feeder layer. However, the rapid growth of the Lof(11-10) cells depleted the nutrients from these cultures, and thus inhibited the proliferation and differentiation of the CD34+ hematopoietic progenitors in the co-culture system. To circumvent this problem, a 14-day hematopoietic methylcellulose culture containing 20~
conditioned media from the parent Lof(11-10) culture was used to support CD34+ cell growth and differentiation into cell populations designated as CFU-M, CFU-G, and CFU-GM colonies.
Colony growth was detected using standard in vitro assays.
The Lof(ll-10) cells supported colony formation similar to the conditioned media obtained from either the 5637 or the GCT cell lines (Tables 2 and 3). Both the 5637 and GCT lines cannot be used in the SCID mouse because of their transformed phenotype, which causes tumor formation. The Lof(11-10) cells are immortalized and will not form tumors in mice.
wo 96117627 PCl~US95l~5986 Table 2: Human CD34+ Bone Marrow Derived Cells Conditioned Media BFU-E CFU-GM
GCT 72+/-12 43+/-5 5637 77+/-6 49+/-2 Lof(ll-10) 55t/-5 43+/-1 Table 3: Monkey CD34+ Bone Marrow Derived Cells Conditioned Media CFU-GM
GCT 28+/-5 5637 23+/-4 Lof(11-10) 22+/-2 Example 3: Reconstitution of SCID Mice with Lof(11-10) Cells The objective in reconstituting SCID mice was to establish a microenvironment that would provide a substratum on which primitive human CD34+ hematopoietic cells could adhere and that would nurture the human CD34+ cells by producing human cytokines. To reconstitute the SCID mice, each mouse was gamma irradiated with either 200 rads (non-lethal) or 400 rads ~lethal). The mice were irradiated to provide an internal space within which the CD34+ cells could repopulate. Four hours after irradiation, the mice were injected intraperitoneally (i.p.) with 5 x 10 Lof(ll-10) cells obtained as described above. As controls, two SCID
mice were injected with Iscove's media without Lof~11-10) cells.
Five to seven days after the injection of Lof(11-10) cells, each mouse was given an intravenous (i.v.) injection of either 3 to 5 purified human CD34+ cells or 2 to 5 purified monkey CD34+ cells. The bone marrow-derived CD34 cells were obtained ~rom the posterior iliac crest under W O96/17627 PCTrUS95/15986 local anesthesia from healthy donors with informed consent.
Briefly, bone marrow aspiration was performed into a 20 ml syringe containing EDTA as an anticoagulant. Bone marrow cells were diluted 1:2 with PBS and were subjected to ficoll-hypaque density gradient centrifugation. Interphase mononuclear cells were washed twice in PBS and were further purified using magnetic beads linked with the high affinity CD34 monoclonal antibody K6.1. The monoclonal antibody K6.1 was produced by fusing SP-2/0-AG14 plasmacytoma cells ((ATCC), Rockville, MD) with splenocytes from a BALB/cByJ
mouse (Jackson Laboratory, Bar Harbor, ME) which had been immunized with viable KG-la cells ~ATCC, Rockville, MD).
After magnetic selection, beads were chemically dissociated from the cells and the cells were referred to as CD34-positive cells (Kirshenbaum et al., J. Immunol. 14:1410, 1991) .
The time interval between the injection of the two cell populations was to allow engraftment of the Lof(11-lO) cells before the introduction of the CD34+ cells. By first reconstituting the SCID mice with the Lof(ll-10) cells, human cytokines needed to nourish the CD34+ hematopoietic pluripotent stem, progenitor and blood lineage precursor cells were supplied. In addition, the Lof(11-10) cells served as a substratum for cell "homing~ and the early attachment of the CD34+ cells (1 to 10 days) during reconstitution.
In the initial experiments, SCID mice were irradiated with 400 rads. Mice (n=2) injected with media without Lof(11-10) cells died at 7 days, whereas mice (n=5) receiving Lof(11-10) cells lived to 50 days post-irradiation. ~See Figure 2). This suggests that the Lof(11-10) cells reconstituted the mice and transiently protected the mice from the lethal irradiation resulting in a 6-fold increase in survival of the mice.
The presence of Lof(11-10) cells in the SCID mice was confirmed using DNA PCR. Briefly, DNA was purified from both the spleen and bone marrow cells from either control or _ . .. . . . . .. . . . . .
WO 96117627 PCT/US95~15986 Lof(11-10)-injected mice. Aliquots (1 ~g) were amplified with 0.5 ~M sequence-specific primer pairs for either T-antigen or mouse ribosomal 28S gene, in a 50 ~1 reaction volume containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM
MgC12, 200 mM dNTPs, and 1.5 units of Taq DNA polymerase for 28 cycles. The specific primer pairs used were as follows:
SV40 large T: 5'-CCTGGTGTTGATGCAATGTACTGCAAAC (SEQ ID
NO:28) 3'-CACAAACAATTAGAATCAGTAGTTTAACAC (SEQ ID
NO:29) MOUSE 28s rRNA: 5'-GTCGACCA~~ lCCTTTGAGGTCCG (SEQ ID NO:30) 3'-GCTGGACAAGCAAAACAGCCTTAAATCG (SEQ ID
NO:31).
The PCR profile consists of 94~ C for 1 minute, 60~ C for 1 minute, and 72~ C for 3 minutes, for the denaturation, annealing, and extension reactions, respectively.
The amplified products were separated on 1.2~ agarose gels in the presence of 0.5 ~g/ml ethidium bromide, transferred to nylon membranes, and probed with 32p end-labeled oligonucleotides for either T-antigen or mouse 28S
gene, respectively. The probes used were as follows:
SV40 large T: CGATTGCTTTAGAATGTGGTTTGGACTTGATC (SEQ ID
NO:32) MOUSE 28s rRNA: CCTCCCTGTCT~llllATGCTTGTGATC (SEQ ID NO:33).
The probe sequences represented regions internal to, and not overlapping with, primers used for amplification.
Hybridization signals were quantified directly from the nylon membranes using a PhosphorImager scanner with ImageQuant software form Molecular Dynamics (Sunnyvale, CA). The results of the DNA PCR experiments are shown in Figure 3.
The presence of circulating human Ik-6 demonstrates that the Lof(ll-10) cells are functional and expressing their repertoire of human cytokines. The measurement of human IL-6 W O96/17627 PCTrUS95/15986 was done on plasma obtained ~rom the blood of ~nlm~ls, by ELISA analysis. (Table 4.) WO 96117627 PCT/US9S~lS986 Table 4: Quantitation of Human IL-6 from Reconstituted SCID
Plasma by ELISA
Expt # Conditionl IL6(pq/ml) 1 Control2 ~nD3 (200 rad, 4-6 wks) Lof(11-10) reconstituted2 39 (200 rad, 4-6 wks) Mouse # 1 2 3 4 2 Monkey CD34 reconstituted ND ND ND ND
(200 rad, 6 wks) Lof(11-10)+ monkey CD34 reconstituted2 25 11 ND 16 (200 rad, 4-6 wks) 50 x 106 Lof(11-10) injected i.p.; 0.5 106 monkey CD34+ injected i.p.
2 25-75 ml of plasma from 5 mice were pooled for analysis 3 ND = non detected, OD~negative standard control value Additional evidence that the human cytokines expressed from the injected Lof(11-10) cells are circulating and potentially capable of supporting the engraftment of intravenously injected human CD34+ cells comes from their influence on the bone marrow progenitor cells of the mice, as measured by methylcellulose colony formation (Table 5).
Whereas irradiation reduces the number of colonies in methylcellulose assays, the animals inoculated with Lof(11-10) cells showed a restoration of colony formation in spite of irradiation, suggesting that the Lof(11-10) cells are expressing radioprotective cytokines that can reverse the negative effects of irradiation on mouse progenitor cells P20.
CA 022072l6 1997-06-06 ~ABLE 5: COLONY FORMATION FROM SCID MOUSE BONE MARROW
Expt. Time After Relative Treatment RadiationCFU-GM Colonies Percentaqe SCID #1 SCID #2 SCID #3 1 No radiation 6 Wks 74+/-15 55+/-7 -- 100 200 rads 21+/-7 10+/-7 28+/-830 200 rads + 53+/-9 34+/-11 93+/-1293 Lof(11-10) 2 No radiation 6 Wks 57+/-33 -- -- 100 200 rads 10+/-6 -- -- 17 200 rads + 64+/-25 57+/-21 122+/-18 142 Monkey CD34 3 No radiation 8 Wks 152+/-21 -- -- 100 200 rads 15+/-3 __ __ 10 200 rads + 84+/-18 79+/-9 -- 54 Monkey CD34 200 rads + 67+/-25 169+/-7 112+/-15 76 Lof(11-10) +
Monkey CD34+
The ultimate demonstration that the Lof(11-10) cells will support human and primate CD34+ cells comes from the fact that secondary intravenous injection of the animals results in the presence of CD34+ cells within the mouse bone marrow after 3 weeks. (Figure 4.) The spleen and bone marrow compartments of the SCID mice were analyzed to determine whether Lof(11-10) or CD34+
engraftment occurred in these compartments. The Lof(l1-10) cells when injected intraperitoneally into the irradiated mice were found to migrate to the spleens. (Figure 3.) The CD34+ cells detected in the bone marrow of the mice were derived from the human CD34+ cells as indicated by the fact that they are class 2 positive, expressing HLA-DR alpha transcripts by reverse transcriptase dependent RNA PCR.
Lof(11-10) cells are class 1 positive, but class 2 negative.
Additional evidence that the PCR signals observed in the bone marrow are CD34+ cells derived comes from the lack of detection of SV40 T-antigen by DNA-PCR in these preparations.
Further characterization of state of differentiation of the W O 96/17627 PC~US95/15986 CD34+ cells within the bone marrow will be done by following the expression of various cell sur~ace receptors using reverse transcriptase dependent RNA PCR.
* * * * *
All publications mentioned hereinabove are hereby incorporated in their entirety by reference.
While the foregoing invention has been described in some detail for purposes of clarity and underst~n~;ns, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.
W O 96tl7627 PCTnUS9S/15986 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Mosca, Joseph D.
Gartner, Suzanne Kessler, Steven Hall, Eric Kaushal, Sumesh (ii) TITLE OF INVENTION: System For The Maintenance, Growth And Differentiation Of Human And Non-Human Primate Pluripotent Stem, Progenitor And Mature Bone Marrow Cells (iii) NUMBER OF SEQUENCES: 33 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Finnegan, Henderson, Farabow, Garrett ~ Dunner (B) STREET: 1300 I Street, N.W., Suite 700 (C) CITY: Washington (D) STATE: D.C.
(E) COUNTRY: USA
(F) ZIP: 20005 (v) COM~U1~K READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COM~U1~K: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version ~1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/352,957 (B) FILING DATE: 09-DEC-1994 (C) CLASSIFICATION:
(vii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Fordis, Jean B.
(B) REGISTRATION NUMBER: 32,984 (C) REFERENCE/DOCKET NUMBER: 04995.0010-00000 (viii) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (202) 408-4000 (B) TELEFAX: (202) 408-4400 W 096/17627 P ~ ~US95~IS9~6 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
- (A) LEN~j1~: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOhECUhE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) L~;N~1~: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
TGACTGA~AG TCTATGACTT CTTGG 25 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) hENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECUhE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
W O96/17627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) hENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
W O96/17627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
- (A) L~N~l~: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: singl e (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:s:
W O96/17627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~l~: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
GGGA~ACTGA CGACCCTCGG TC 22 (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2 5 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (~enomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
W O 96/17627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
(2) INFORM~TION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
W O96/17627 PCTrUS95/1~986 (2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
WO96117627 pcT~sss/lsss6 (2) INFORMATION FOR SEQ ID NO:l9:
(i) SEQUENCE CHARACTERISTICS:
(A) L~lH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l9:
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
(2) INFORMATION FOR SEQ ID NO:2l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
W O96117627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
t2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
GGAACCTGCA G~lllllGGT GCAGGAGGAC 30 (2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
W O96/17627 PCTrUS95115986 (2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
(2) INFORM~TION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~l~: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (~ STR~NDEDNESS: siP~gle (D) TOPOLOGY: linear tii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
~ CCTCCCTGTC TCTTTTATGC TTGTGATC 28
OF HUMAN AND NON-HUMAN PRIMATE PLURIPOTENT STEM, PROGENITOR AND MATURE BONE MARROW CELLS
SPECIFICATION
Backqround of the Invention Field of the Invention The present invention relates to the use of an immortalized human cell line to create a human microenvironment in mice for the study of human disease states. In this human microenvironment, cells such as human and non-human primate pluripotent stem cells can be maintained and differentiated. In particular, the present invention relates to the injection of an immortalized human stromal cell line (such as Lof(11-10)) into mice to create a human microenvironment supplying human cytokines that are necessary to support the engraftment, maintenance and differentiation o~ human and non-human primate CD34+ stem cells. Such a hllm~n microenvironment provides a valuable animal model for the study of human hematopoiesis.
Description of the Prior Art Biomedical research relies heavily on ~n;m~l models to gain an underst~n~ng of the various disease states in human.
Using animal models, researchers hope to gain an understanding of disease states which will enable them to intervene in the disease process. Animal models have been successfully used to study a range of human diseases, everything from the safety of aspirin and metal metabolism to bacterial and viral infections. For example, mice have been used to investigate Alzheimer's disease (Wi et al., Chunq Kuo Chunq Hsi I Chieh Ho Tsa Chih (China) 12:622, 1992), staphylococcal infection (Bel'skii et al., Zh. Mikrobiol EPidemiol. Immunobiol. (USSR) 3:16, 1989), encephalopathy (Ross et al., Neurotoxicoloqy 9:581, 1988), ankylosis W O96/17627 PCTrUS95115986 (Mahowald et al., Arthritis Rheum. 31:1390, 1988), autoimmunity (Roberts et al., J. Com~. Pathol. (Enqland) 100:391, 1989), systemic lupus (Mendlovic et al., Proc. Natl.
Acad. Sci. USA 85:2260, 1988), epilepsy (King et al., EPilePsia 30:257, 1989), insulin-dependent diabetes (Gottlieb et al., Diabetes Care 11:29, 1988), connective tissue disease (Rosenberg N.L., Arthritis Rheum. 31:806, 1988~, and copper metabolism (Shiraishi et al., Biol. Neonate (Switzerland) 54:173, 1988). Rats have also served as successfully ~n~m~l models for studying cystic fibrosis (Hunsinger et al., Med.
HYpotheses (Enqland) 28:81, 1989), osteoporosis (Yamazaki et al., J. Bone Miner Res. 4:13, 1989), and obesity and hypertension (Crandall et al., J. AP~l. Physiol. 64:1094, 1988).
Animal species other than rodents have also been used successfully to study human diseases. Pigs have been used to investigate E. coli infection (Sarmiento et al., Am. J. Vet.
Rçs. 49:1154, 1988), acetaminophen (Henne-Bruns et al., Res.
Ex~. Med. (GermanY) 188:463, 1988), asthma (Karol M.H., Bull.
Eur. PhysioPathol. Respir. (Enqland) 23:571, 1987), and herpes virus infection (Hsiung et al., Antiviral Res.
(Netherlands) 12:239, 1989), while sheep have been employed to study periodontitis (Ismaiel et al., J. Periodontol.
60:279, 1989) and chronic venous disease (Jessup et al., J.
Vasc. Surq. 8:569, 1988). Chronic subluxation (De Boer et al., J. ManiPulative PhYsiol. Ther. 11:366, 1988) and respiratory distress syndrome (Lachmann B., Dev. Pharmacol.
Ther. (Switzerland) 13:164, 1989) have been studied in adult and fetal rabbits, while hyperoxaluria (Danpure et al., J.
Inherit. Metab. Dis. (Netherlands) 12:403, 1989) has been studied in felines. Arthritis has been studied in both rats (Barthold et al., Ann. NY Acad. Sci. 539:264, 1988) and rhesus monkeys (Pritzker et al., PR Health Sci. J. (Puerto Rico) 8:99, 1989). HIV infection has been intensively studied using such animal models as chimpanzees, gibbons, mice, rabbits, baboons, and rhesus monkeys ~Spertzel R.O., Antiviral Res. (Netherlands) 12:223, 1987).
r Where suitable animal models are not available, however, the study of the disease, and its treatment, may be severely hampered. In particular, the study of hl~m~n hematopoiesis has been hampered by the lack of an animal model for studying hematopoietic cells. The lack of a suitable animal model is especially keen today with the emergence of gene therapy for hllm~n diseases. Presently, the only available means of evaluating a given gene therapy is a clinical trial - a costly, complex and time-consuming endeavor. Accordingly, an ~ni ~1 model for studying the introduction of genetic material into the human pluripotent stem cell would be a major advance for the field.
Hematopoiesis, the formation of mature blood cells, involves a complex scheme of multilineage differentiation (Metcalf, Nature 339:27-30, 1989). In the bone marrow, pluripotent stem cells proliferate and differentiate into progenitor cells which then develop into different types of mature blood cells (Gordon et al., Bone Marrow Trans~lant 4:335, 1989; Dexter et al., Ann. Rev. Cell Bio. 3:423, 1987).
Indeed, the pluripotent stem cell, identified by the presence of the CD34 hematopoietic cell surface antigen, is capable of differentiating and giving rise to cells of all hematopoietic lineages (Sprangruide et al., Science 241:58, 1988).
Two animal models, based on the severe combined immunodeficiency (SCID) mouse, have been developed to study the growth and differentiation of human bone marrow cells, the source of hematopoietic cells. Both of these models, however, have drawbacks and disadvantages which limit their usefulness. In the first system, established by John Dick, human cytokines are supplied by systemic administration to the SCID mice transplanted with human bone marrow (Lapidot et al., Science 255:1137-1141 (1992)). (See also, Dick et al., Sem. Immunol. 3:367-378 (1991).) This system is very expensive, re~uiring 3-times a week injections of purified recombinant cytokines.
The second system, developed by Jim McCune, involves the surgical implantation of human fetal tissues into SCID mice W O 96tl7627 PCTrUS95/lS986 (McCune et al., Science 241:1632-1639 (1988); and Kaneshima et al., Nature 348:561-562 (1990)). In the McCune system, human fetal liver, human fetal thymus and/or human fetal lymph nodes are implanted into SCID mice. These mice support the differentiation of mature human T cells and B cells. The McCune system has also succeeded in sustaining active human hematopoiesis in SCID mice implanted with human fetal bone (Kyoizumi et al., Blood 79:1704-1711 (1992)). The surgical procedures, however, which must be conducted on each mouse with the McCune system are time consuming and costly. In addition, the availability of fetal tissue is limited and its use makes this approach controversial.
SUMMARY OF THE INVENTION
Accordingly, it is one object of the present invention to provide an animal model that can be used as a pre-clinical assay to evaluate different proposed gene therapies by testing whether the therapy effectively corrects the given deficiency.
It is a further object of the present invention to provide an inexpensive, straight forward, and versatile means of studying the growth and differentiation of human bone marrow cells.
It is another object of the present invention to provide a human microenvironment in mice using an immortalized human cell line.
Various other objects and advantages of the present invention will be apparent from the drawings and the following description of the invention.
To accomplish these objectives, the present invention relates to a method of engrafting human or non-human primate stem cells in a mouse to create an animal model useful for the study of hematopoietic cells. In one embodiment, the cells are primitive stem cells that have the capability of differentiating into all hematopoietic cells. In a preferred embodiment, the stem cells are CD34+. In a particular embodiment, the method comprises irradiating the mouse with a CA 022072l6 l997-06-06 W 096/17627 PCTAUS95/lSg86 lethal or non-lethal dose of radiation; administering to the irradiated mouse immortalized human or non-hllm~n primate bone marrow stromal cells which express cytokines supporting growth of stem cells; and administering to the irradiated mouse purified human or non-human primate stem cells.
In another embodiment, the present invention relates to a method of testing the effectiveness of a gene therapy protocol against an infectious agent such as HIV. The method comprises irradiating a first and a second mouse with a lethal or non-lethal dose of radiation; administering to the irradiated mice immortalized human or non-human primate bone marrow stromal cells which express cytokines supporting growth of CD34+ stem cells; introducing a proposed therapeutic gene segment into a first group of human CD34+
stem cells; purifying the cells from the first group of CD34+
stem cells expressing the gene segment; introducing a control gene segment into a second group of human CD34+ stem cells;
administering the purified CD34+ stem cells expressing the gene segment to the first irradiated mouse and administering the control cells to the second irradiated mouse; challenging both irradiated mice with the retrovirus; and comparing the survival of the hllm~n CD34+ stem cells from the two mice.
In a further embodiment, the present invention relates to an animal model for the study of human hematopoiesis. This model comprises a rodent into which human or non-human primate CD34+ stem cells have been engrafted in the present of immortalized hllm~n or non-human primate bone marrow stromal cells. In a preferred embodiment, the rodent is a mouse, such as a SCID mouse.
BRIEF DESCRIPTION OF THE DRAWINGS
d Figure 1 shows the relative expression of cytokine mRNA
transcripts in the human stromal cell line Lof(l1-10)~
Figure 2 shows the survival of lethally irradiated SCID
mice reconstituted with the human stromal cell line Lof(11-10) .
W O96/17627 PCTrUS95/15986 Figure 3 shows the detection of Lof~ 10) cells in SCID
mice by DNA polymerase chain reaction (PCR).
Figure 4 shows the detection of human and monkey CD34 derived cells in the bone marrow compartment of SCID mice by reverse transcriptase (RT)-dependent RNA PCR. Lanes 1-4 show mice receiving 1 x 10 Lof(11-10) cells by intraperitoneal injection (i.p.) plus 3 x 105 human CD34+ cells by intravenous injection (i.v.) Lane 5 shows mice receiving 1 x 107 Lof(11-10) cells i.v. plus 2 x 105 monkey CD34+ cells i.v. Lanes 6-8 show mice receiving 1 x 10 Lof(11-10) cells i.p. plus 2 x 10 monkey CD34+ cells i.v.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method of engrafting human or non-human primate pluripotent stem cells in a rodent. Using severe combined immunodeficiency (SCID) mice, the inventors developed a method for engrafting human or non-human primate pluripotent CD34+ stem cells into the SCID
mouse. Although mice were utilized in the development of the present method, any rodent may be used. Preferred rodents include SCID mice; these mice have mutated scid genes which prevent production of mature T cells and B cells by the mice.
All other hematopoietic lineages are produced as normal in these mice.
Pluripotent stem cells can be defined functionally as well as phenotypically. Functionally, pluripotent stem cells are those hematopoietic cells having the capability of multilineage differentiation and self-renewal. Pluripotent stem cells can also be defined phenotypically by cell sur~ace markers. For example, human stem cells have been characterized as CD34+ CD38-, HLA-DR-, THY+, and Rhl23-.
In the present method, human and non-human primate pluripotent stem cells are engrafted in a rodent, preferably a mouse. To engraft human and non-human primate stem cells so that the cells are maintained and differentiated in the mouse, the mouse is first irradiated with a lethal or non-lethal dose of radiation. For example, each mouse can be exposed to 200 or 400 rads o~ gamma irradiation. Once irradiated, the mice are given a dose of immortalized cells which support the growth of stem cells. In one embodiment, the supportive cells are immortalized bone marrow stem cells which express cytokines. Finally, the mice are given an injection of purified hl~m~n or non-human primate CD34+ cells.
The cells engrafted into the rodent are preferably CD34+
stem cells obtainable from bone marrow, peripheral blood or cord blood. These cells can be isolated from human or non-human primate bone marrow or blood using methods known in the art. Other cells useful in this engraftment method include, but are not limited to, fetal liver and fetal thymus.
Immortalized bone marrow stromal cells are administered to the irradiated mice to provide, within the mice, a substratum on which later administered primitive hematopoietic cells, such as CD34+ stem cells, can adhere.
These stromal cells also nurture such cells by producing the cytokines necessary for their growth and differentiation.
The immortalized bone marrow stromal cells serve as a microenvironment within the mouse where stem cells engraftment, differentiation, and self-renewal can occur.
The immortalized stromal cells preferably produce human cytokines. Suitable immortalized bone marrow stromal cells include, but are not limited to, the Lof(11-10) cell line.
The Lof(11-10) cell line is preferred because these cells naturally produce human cytokines and, therefore, can support the growth of CD34+ cells in vitro. The Lof(11-10) cell line produces Il-1~, IL-1~, IL-6, IL-8, GM-CSF, M-CSF, G-CSF, and SCF (stem cell factor). In addition, these cells are immortalized using the SV40 large T-cell antigen and, unlike transformed cells, do not produce tumors when administered to mlce .
Like the Lof(11-10) cell line, the immortalized bone marrow stem cells employed in the present invention may naturally produce the desired cytokines. Alternatively, the bone marrow stem cells can be genetically engineered, using standard methods known in the art, to produce the desired _ _ _ _ _ _ _ _ _ _ _ _ _ . . . . . .
W O 96/17627 PCTnUS95/15986 cytokines or other desired supporting components. For example, the Lof(ll-lO) cell could be modified to further produce such human cytokines as IL-3, additional SCF, IL-7 or IL-2.
The immortalized bone marrow stromal cells and the purified CD34+ cells are administered in amounts sufficient to promote engraftment of the CD34+ cells. Preferably, 0.1-5.0 x 107 bone marrow stromal cells are administered to each rodent, more preferably each rodent is given 0..1, 0.5, 1.0 or 5.0 x 10 cells. Preferably, 0.1 - 5.0 x 105 CD34+ cells are given to each rodent. More preferably, each rodent is given a dosage of 0.1, 0.5, 1.0 or 5.0 x 105 CD34+ cells.
These two populations of cells can be administered to the mouse simultaneously or sequentially. Preferably, the immortalized bone marrow stromal cells are administered first intraperitoneally (i.p.), followed by sequential administration of the purified CD34+ cells intravenously (i.v.). For example, the purified CD34+ cells can be administered about 10 days after the immortalized bone marrow stromal cells are administered, preferably 2-7 days after the immortalized bone marrow stromal cells are A~m; nl stered.
The present invention is an inexpensive, straight forward, and versatile system for engrafting human and non-human primate CD34+ cells in the mouse animal model. The method is relatively inexpensive as the immortalized bone marrow stromal cells are capable of growth in cell cultures.
For example, ~of(11-10) cells can be grown to 1 x 10 per T225 flask, which is enough cells to introduce into one mouse. The method is straight forward in that the injection of the immortalized bone marrow stromal cells is easy to perform and provides a continuous supply of human cytokines in the mouse. Finally, the method is versatile. The immortalized bone marrow stromal cells can be made to express additional htlmAn growth factor, surface receptors and/or cytokine genes.
Mice engrafted with human stem cells such as CD34+ cells, according to the present invention, produce all lineages of W 096117627 PCTAUS95/15g86 hllm~n blood cells. The engrafted CD34+ cells are able to proliferate and differentiate into all blood cell lineages including human T cells and human B cells, thereby establishing a htlm~n hematopoietic microenvironment in the mouse. This animal model for human hematopoiesis has several uses. For example, the mice of the present invention can be used as a model for studying infectious diseases in vivo.
This model can also be used to screen compounds for antiviral activity in vivo. This mouse model can also be used to assay for hematopoietic growth factors, immune modulators and/or immune toxins. Finally, mice engrafted with human CD34+
cells can be used in the production of human monoclonal antibodies and hl~m~n cytolytic T cell clones.
The present invention also relates to a method of testing the effectiveness of gene therapy protocols against infectious agents such as human immunodeficient virus (HIV), human cytomegalovirus (CMV), human papilloma virus (HPV), and Epstein-Barr virus ~EBV). In this testing method, putative therapeutic genetic material is introduced into the human CD34+ cell and the CD34+ cells are then engrafted in a rodent to determine whether the introduction of the genetic material prolongs the survival of the CD34+ cells and their progeny in vivo. The genetically engineered CD34+ cells are engrafted in, for example, a mouse as described above. The mouse is then challenged with the infectious agent and survival of the human CD34+ cells and their progeny is determined.
For example, the present testing method can be used to determine the effectiveness of a gene therapy protocol against HIV, the causative agent of AIDS. An effective gene therapy protocol against HIV infection would confer resistance against HIV to cells in vivo. If resistance to HIV infection can be conferred upon cells in vivo using a - particular gene therapy protocol, further studies would be warranted to optimize the therapeutic benefits of the molecular intervention in AIDS patients.
In the method of the invention, a proposed anti-HIV gene is introduced into human CD34+ cells and the cells expressing W O96tl7627 PCTrUS95/15986 the gene are then purified. Introduction of the proposed anti-HIV gene into CD34+ cells can be accomplished by techniques standard in the art such as a viral-mediated vector system. Purification of the expressing CD34+ cells can be easily done by techniques in the art such as either drug selection or surface expression of genes co-introduced with the anti-HIV gene. A control gene is introduced into a separate aliquot of human CD34+ cells. The control gene, for example, contains the proposed anti-HIV gene but has a frameshift which abrogates expression of the proposed anti-HIV gene.
Effects of the proposed anti-HIV gene and the control anti-HIV gene can be analyzed using either one or two populations of mice that have been irradiated with a lethal or non-lethal dose of radiation and given a dose of immortalized human bone marrow stromal cells which express cytokines supporting the growth of CD34+ cells. If two mice populations are used, one population is administered the human CD34+ cells expressing the proposed anti-HIV gene and the other is given the human CD34+ control cells. The mice are then challenged with HIV. The half-life and survival of the human CD34+ cells and their progeny which express the proposed anti-HIV gene are compared with the CD34+ control cells. These two populations can be distinguished using techniques familiar in the art such as a limited dilution PCR
of cells derived from the spleen and bone marrow with primers specific for each vector. In this way, the number of cells which persist can be determined as a function of time, and the half-life of cells transduced with each vector can be assessed.
The present system can also be used to assay for the ' successful introduction of a therapeutic gene into the true stem cells, which are capable of self-renewal and life-long expression. This can be determined by PCR analyses of human spleen colonies growing in SCIDs 14 days after CD34+ cells injection. These colonies represent the earliest assayable cells derived from the pluripotent stem cell. Introduction W O 96/17627 ~CT~US95J15g86 of an effective therapeutic into this cell population would ensure a one-time gene therapy in recipient patients.
This is important because only 0.1 to 1 percent of the CD34+ cells are true pluripotent stem cells; the rem~;n;ng 99 percent of the CD34+ cells are committed progenitors which will give raise to various blood lineages. Thus, the expression of a therapeutic gene in the CD34+ population does not necessarily mean that the therapeutic is in the stem cell. Although the expression of a therapeutic would be useful in the mature cells in the blood, the life-span of these mature cells is finite. Introduction of the therapeutic into the pluripotent self-renewing stem cell insures a continuous supply of committed progenitors which in turn insures a continuous supply of mature cells in the blood armed with the therapeutic.
By way of example, in the case of HIV, the anti-HIV gene would be present in the mature T cells and monocytic cells of an HIV in~ected patient, potentially allowing that individual to lead a normal life in spite of harboring the AIDS virus.
At the present time, a functional assay ~or the introduction of a therapeutic into the stem cell is nonexistent and would have to wait for the outcome of a clinical trial or a bone marrow transplant in primates. The use of the spleen colony assay of the present invention for human cells within the SCID spleen would greatly facilitate the development of the procedures to assay for the introduction of the therapeutic gene into human stem cells, insuring the continuous supply of committed progenitors and mature cells armed with the antiviral gene.
The present invention further relates to a method of treating patients exposed to radiation to reduce recovery time. Radiation is currently used to treat different forms of cancer including leukemia and to treat patients undergoing bone marrow transplantations. When patients are exposed to radiation for bone marrow transplants, all of their bone marrow is destroyed, including their progenitor cells (which give rise to the mature cells in the blood) and the stromal =
W O96/17627 PCTrUS95115986 cells (which nurture the stem and progenitor cells to renew, grow and differentiate). The window of time (1 to 2 months) between whole body irradiation and the growth/differentiation of the "newly" introduced bone marrow cells into the patient is the most critical time in bone marrow transplantation.
This is the time when the patient is most susceptible to either rejection (host versus graft disease) or opportunistic infections (due to an incompetent immune system).
Cytokine therapy has shown promise when used during the period of time between whole body irradiation and growth/
differentiation of the new cells, suggesting that the establishment of a functional stromal layer is essential to supply the cytokines needed to allow stem and progenitor cell growth. The "newly" introduced bone marrow cells will, in time, establish their own stromal layer; however, the introduction of a stromal cell line expanded in vitro and introduced with the "new" marrow may reduce this window of uncertainty. The stromal cells can be obtained from the patients' own marrow or from their donor by procedures similar to those used to establish the Lof(ll-10) cell line.
For the purposes of illustrating a preferred embodiment of the present invention, in the following non-limiting examples, the immortalized human stromal cell line Lof(ll-10) was used to reconstitute SCID mice with human and monkey CD34+ cells. It is, however, to be understood that the discussion generally applies to the reconstitution of any mouse with human cells capable of producing cytokines.
- EXAMPLES
Example 1: Lof(11-10) Cells Produce Cytokines Which Su~ort In Vi tro CD34+ Cell Growth Lof(11-10) is a hllm~n immortalized stromal cell line established from hllm~n bone marrow by transfection of a plasmid containing a SV40 large T antigen (pSV3gt) as described by S.W. Gartner (Establishment and Characterization of Human Bone Marrow Stroma-Derived Cell Lines Transformed Following Transfection with Cloned SV40 Early Region DNA
(1984) (Ph.D. dissertation, Stanford University). To determine whether Lof(ll-lO) cells produce cytokines which are required to support cell growth, Lof(ll-10) cells were grown in T162 tissue culture flasks for 10 days. The expression of cytokine mRNA transcripts in the hof(ll-10) cultures was then detected using reverse transcriptase (RT)-dependent RNA PCR analysis.
Briefly, total RNA was isolated from the cultured Lof(11-10) cells using the RNAzol B RNA isolation solvent (Tel-Test) according to manufacturer's instructions. Ten micrograms of purified RNA were incubated at 37~ C for 30 minutes with 100 units of RNase-free DNase in 0.1 M sodium acetate, 5 mM MgC12 in a 50 ~l reaction, followed by phenol/chloroform extraction and ethanol precipitation. Samples of 5 ~g of DNase-treated RNA were converted to cDNA by primer extension with 0.1 mg/ml random primers, and 600 units of Moloney murine leukemia virus RT (Bethesda Research Laboratories).
The RNA and the random primers were heated to 70~ C for 10 minutes followed by quick cooling on ice. The mixture was then incubated for 1 hour at 37~ C in a 40 ~l reaction volume containing 50 mM Tris-HCl (pH 8.3), 40 mM KCl, 6 mM
MgCl2, 10 mM DTT and 750 ~M dNTPs. The RT reaction was terminated by heating at 90~ C for 5 minutes before PCR
amplification.
Aliquots of the DNase-treated RNA, with and without conversion to cDNA by reverse transcriptase, were amplified with 0.5 ~M sequence specific primer pairs in a 50 ~l W O 96/17627 PCTrUS95/15986 reaction volume containing 2 ~1 of reverse-transcribed cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgC12, 200 mM dNTPs, and 1.5 units of Taq DNA polymerase (Perkin-Elmer/Cetus) for 28 cycles. The specific primer pairs used were as follows:
I~-1~: 5'-ATGGCCAAAGTTCCAGACATGTTTG (SEQ ID N0:1) 3'-GGTTTTCCAGTATCTGAAAGTCAGT (SEQ ID N0:2) IL-l~: 5'-ATGGCAGAAGTACCTAAGCTCGC (SEQ ID NO:3) 3'-ACACAAATTGCATGGTGAAGTCAGTT (SEQ ID N0:4) IL-6: 5'-ATGAACTCCTTCTCCACAAGCGC (SEQ ID N0:5) 3'-GAAGAGCCCTCAGGCTGGACTG (SEQ ID NO:6) IL-8: 5'-ATGACTTCCAAGCTGGCCGTGCT (SEQ ID N0:7) 3'-TCTCAGCCCTCTTCAAAAACTTCTC (SEQ ID NO:8) GM-CSF: 5'-ATGTGGCTGCAGAGCCTGCTGC (SEQ ID N0:9) 3'-CTGGCTCCCAGCAGTCAAAGGG (SEQ ID N0:10) G-CSF: 5'-GAGTGTGCCACCTACAAGCTGTGCC (SEQ ID N0:11) 3'-CCTGGGTGGGCTGCAGGGCAGGGGC (SEQ ID N0:12) M-CSF: 5'-GAGGAGGTGTCGGAGTACTGTAGCCACATG (SEQ ID N0:13) 3'-CATAGAAAGTTCGGACGCAGGCCTTGTCATG (SEQ ID NO:14) TGF~: 5'-ATGGTCCCCTCGGCTGGACAG (SEQ ID N0:15) 3'-GGCCTGCTTCTTCTGGCTGGCA (SEQ ID N0:16) SCF: 5'-CCACTGTTTGTGCTGGATCGCAGCGCTGCC (SEQ ID N0:17) 3'-GTCATCCACTATATTCACAAGTTTGTCTATG (SEQ ID N0:18).
The PCR profile consisted of 94~ C for 1 minute, 60~ C for 1 minute, and 72~ C for 3 minutes, for the denaturation, annealing, and extension reactions, respectively. The samples were incubated at 94~ C for 3 minutes before the start of the PCR profile and a final extension time of 20 minutes at 72~ C was provided after the 28th PCR cycle.
The amplified products were separated on 1.2~ agarose gels in the presence of 0.5 ~g/ml ethidium bromide, transferred to nylon membrane, and probed with 32p end-WO 96117627 PCT~US9~ i98C
labeled oligodeoxyribonucleotides having the following sequences:
IL~ CCTTCTATCATGTAAGCTATGGCCCACTCC (SEQ ID NO:19) IL-1~: GGTCCATATGAACTGAAAGCTCTCCACCTC (SEQ ID NO:20) IL-6: GAAAAAGATGGATGCTTCCAATCTGG (SEQ ID NO:21) IL-8: GAACTGAGAGTGATTGAGAGTGGACCACAC (SEQ ID NO:22) GM-CSF: CGCCTGGAGCTGTACAAGCAGGGCCTGCGG (SEQ ID NO:23) G-CSF: CTGCAGGCCCTGGAAGGGATCTCCCCCGAG (SEQ ID NO:24) M-CSF: GAGGACACCATGCGCTTCAGAGATAACACC (SEQ ID NO:25) TGF~: GGAACCTGCAG~lllllGGTGCAGGAGGAC (SEQ ID NO:26) SCF: CCAAAAGACTACATGATAACCCTCAAATATG (SEQ ID NO:27).
The probe sequences represented regions internal to, and not overlapping with, primers used for amplification.
Hybridization signals were quantified directly from the nylon membrane using a PhosphorImager sc~nner with ImageQuant software form Molecular Dynamics (Sunnyvale, CA).
The results, shown in Figure 1, demonstrate that Lof(11-10) cells produce cytokines, such as IL-lB, IL-8, M-CSF and B-ACTIN, which support the growth of cells, such as the CD34+
stem cell. Additional cytokines with short-lived mRNAs like Il-6, GM-CSF, and G-CSF are also expressed in the present of protein synthesis inhibitors.
Cytokine expression by Lof(11-10) cells, 5637 cells (a human bladder primary carcinoma) and GCT cells (a human fibrous histicytoma) were quantitated using ELISA
immunoassays. The 5637 and GCT cell lines are available from American Type Culture Collection (ATCC), Rockville, MD.
Briefly, measurement of cytokines was performed with culture supernatant using ELISA kits from R & D Systems (Minneapolis, MN) according to the manufacturer's specifications. The results of the ELISA are shown below in Table 1.
W O 96/17627 PCTrUS95/15986 CYtokines (Pq/ml ) Condition Media IL-~ IL-6 GM-CSFSCF
GCT 115 ,300 ~500~10 5637 ~250 ~300 ~500250 Lof(11-10) 200 3665 150 70 Example 2: Lof(11-10) Cells SuPPort In Vitro CD34+
Proqenitor Cells Initially, attempts were made to establish a stroma-dependent long-term bone marrow culture using the Lof(11-10) cells as a stromal feeder layer. However, the rapid growth of the Lof(11-10) cells depleted the nutrients from these cultures, and thus inhibited the proliferation and differentiation of the CD34+ hematopoietic progenitors in the co-culture system. To circumvent this problem, a 14-day hematopoietic methylcellulose culture containing 20~
conditioned media from the parent Lof(11-10) culture was used to support CD34+ cell growth and differentiation into cell populations designated as CFU-M, CFU-G, and CFU-GM colonies.
Colony growth was detected using standard in vitro assays.
The Lof(ll-10) cells supported colony formation similar to the conditioned media obtained from either the 5637 or the GCT cell lines (Tables 2 and 3). Both the 5637 and GCT lines cannot be used in the SCID mouse because of their transformed phenotype, which causes tumor formation. The Lof(11-10) cells are immortalized and will not form tumors in mice.
wo 96117627 PCl~US95l~5986 Table 2: Human CD34+ Bone Marrow Derived Cells Conditioned Media BFU-E CFU-GM
GCT 72+/-12 43+/-5 5637 77+/-6 49+/-2 Lof(ll-10) 55t/-5 43+/-1 Table 3: Monkey CD34+ Bone Marrow Derived Cells Conditioned Media CFU-GM
GCT 28+/-5 5637 23+/-4 Lof(11-10) 22+/-2 Example 3: Reconstitution of SCID Mice with Lof(11-10) Cells The objective in reconstituting SCID mice was to establish a microenvironment that would provide a substratum on which primitive human CD34+ hematopoietic cells could adhere and that would nurture the human CD34+ cells by producing human cytokines. To reconstitute the SCID mice, each mouse was gamma irradiated with either 200 rads (non-lethal) or 400 rads ~lethal). The mice were irradiated to provide an internal space within which the CD34+ cells could repopulate. Four hours after irradiation, the mice were injected intraperitoneally (i.p.) with 5 x 10 Lof(ll-10) cells obtained as described above. As controls, two SCID
mice were injected with Iscove's media without Lof~11-10) cells.
Five to seven days after the injection of Lof(11-10) cells, each mouse was given an intravenous (i.v.) injection of either 3 to 5 purified human CD34+ cells or 2 to 5 purified monkey CD34+ cells. The bone marrow-derived CD34 cells were obtained ~rom the posterior iliac crest under W O96/17627 PCTrUS95/15986 local anesthesia from healthy donors with informed consent.
Briefly, bone marrow aspiration was performed into a 20 ml syringe containing EDTA as an anticoagulant. Bone marrow cells were diluted 1:2 with PBS and were subjected to ficoll-hypaque density gradient centrifugation. Interphase mononuclear cells were washed twice in PBS and were further purified using magnetic beads linked with the high affinity CD34 monoclonal antibody K6.1. The monoclonal antibody K6.1 was produced by fusing SP-2/0-AG14 plasmacytoma cells ((ATCC), Rockville, MD) with splenocytes from a BALB/cByJ
mouse (Jackson Laboratory, Bar Harbor, ME) which had been immunized with viable KG-la cells ~ATCC, Rockville, MD).
After magnetic selection, beads were chemically dissociated from the cells and the cells were referred to as CD34-positive cells (Kirshenbaum et al., J. Immunol. 14:1410, 1991) .
The time interval between the injection of the two cell populations was to allow engraftment of the Lof(11-lO) cells before the introduction of the CD34+ cells. By first reconstituting the SCID mice with the Lof(ll-10) cells, human cytokines needed to nourish the CD34+ hematopoietic pluripotent stem, progenitor and blood lineage precursor cells were supplied. In addition, the Lof(11-10) cells served as a substratum for cell "homing~ and the early attachment of the CD34+ cells (1 to 10 days) during reconstitution.
In the initial experiments, SCID mice were irradiated with 400 rads. Mice (n=2) injected with media without Lof(11-10) cells died at 7 days, whereas mice (n=5) receiving Lof(11-10) cells lived to 50 days post-irradiation. ~See Figure 2). This suggests that the Lof(11-10) cells reconstituted the mice and transiently protected the mice from the lethal irradiation resulting in a 6-fold increase in survival of the mice.
The presence of Lof(11-10) cells in the SCID mice was confirmed using DNA PCR. Briefly, DNA was purified from both the spleen and bone marrow cells from either control or _ . .. . . . . .. . . . . .
WO 96117627 PCT/US95~15986 Lof(11-10)-injected mice. Aliquots (1 ~g) were amplified with 0.5 ~M sequence-specific primer pairs for either T-antigen or mouse ribosomal 28S gene, in a 50 ~1 reaction volume containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM
MgC12, 200 mM dNTPs, and 1.5 units of Taq DNA polymerase for 28 cycles. The specific primer pairs used were as follows:
SV40 large T: 5'-CCTGGTGTTGATGCAATGTACTGCAAAC (SEQ ID
NO:28) 3'-CACAAACAATTAGAATCAGTAGTTTAACAC (SEQ ID
NO:29) MOUSE 28s rRNA: 5'-GTCGACCA~~ lCCTTTGAGGTCCG (SEQ ID NO:30) 3'-GCTGGACAAGCAAAACAGCCTTAAATCG (SEQ ID
NO:31).
The PCR profile consists of 94~ C for 1 minute, 60~ C for 1 minute, and 72~ C for 3 minutes, for the denaturation, annealing, and extension reactions, respectively.
The amplified products were separated on 1.2~ agarose gels in the presence of 0.5 ~g/ml ethidium bromide, transferred to nylon membranes, and probed with 32p end-labeled oligonucleotides for either T-antigen or mouse 28S
gene, respectively. The probes used were as follows:
SV40 large T: CGATTGCTTTAGAATGTGGTTTGGACTTGATC (SEQ ID
NO:32) MOUSE 28s rRNA: CCTCCCTGTCT~llllATGCTTGTGATC (SEQ ID NO:33).
The probe sequences represented regions internal to, and not overlapping with, primers used for amplification.
Hybridization signals were quantified directly from the nylon membranes using a PhosphorImager scanner with ImageQuant software form Molecular Dynamics (Sunnyvale, CA). The results of the DNA PCR experiments are shown in Figure 3.
The presence of circulating human Ik-6 demonstrates that the Lof(ll-10) cells are functional and expressing their repertoire of human cytokines. The measurement of human IL-6 W O96/17627 PCTrUS95/15986 was done on plasma obtained ~rom the blood of ~nlm~ls, by ELISA analysis. (Table 4.) WO 96117627 PCT/US9S~lS986 Table 4: Quantitation of Human IL-6 from Reconstituted SCID
Plasma by ELISA
Expt # Conditionl IL6(pq/ml) 1 Control2 ~nD3 (200 rad, 4-6 wks) Lof(11-10) reconstituted2 39 (200 rad, 4-6 wks) Mouse # 1 2 3 4 2 Monkey CD34 reconstituted ND ND ND ND
(200 rad, 6 wks) Lof(11-10)+ monkey CD34 reconstituted2 25 11 ND 16 (200 rad, 4-6 wks) 50 x 106 Lof(11-10) injected i.p.; 0.5 106 monkey CD34+ injected i.p.
2 25-75 ml of plasma from 5 mice were pooled for analysis 3 ND = non detected, OD~negative standard control value Additional evidence that the human cytokines expressed from the injected Lof(11-10) cells are circulating and potentially capable of supporting the engraftment of intravenously injected human CD34+ cells comes from their influence on the bone marrow progenitor cells of the mice, as measured by methylcellulose colony formation (Table 5).
Whereas irradiation reduces the number of colonies in methylcellulose assays, the animals inoculated with Lof(11-10) cells showed a restoration of colony formation in spite of irradiation, suggesting that the Lof(11-10) cells are expressing radioprotective cytokines that can reverse the negative effects of irradiation on mouse progenitor cells P20.
CA 022072l6 1997-06-06 ~ABLE 5: COLONY FORMATION FROM SCID MOUSE BONE MARROW
Expt. Time After Relative Treatment RadiationCFU-GM Colonies Percentaqe SCID #1 SCID #2 SCID #3 1 No radiation 6 Wks 74+/-15 55+/-7 -- 100 200 rads 21+/-7 10+/-7 28+/-830 200 rads + 53+/-9 34+/-11 93+/-1293 Lof(11-10) 2 No radiation 6 Wks 57+/-33 -- -- 100 200 rads 10+/-6 -- -- 17 200 rads + 64+/-25 57+/-21 122+/-18 142 Monkey CD34 3 No radiation 8 Wks 152+/-21 -- -- 100 200 rads 15+/-3 __ __ 10 200 rads + 84+/-18 79+/-9 -- 54 Monkey CD34 200 rads + 67+/-25 169+/-7 112+/-15 76 Lof(11-10) +
Monkey CD34+
The ultimate demonstration that the Lof(11-10) cells will support human and primate CD34+ cells comes from the fact that secondary intravenous injection of the animals results in the presence of CD34+ cells within the mouse bone marrow after 3 weeks. (Figure 4.) The spleen and bone marrow compartments of the SCID mice were analyzed to determine whether Lof(11-10) or CD34+
engraftment occurred in these compartments. The Lof(l1-10) cells when injected intraperitoneally into the irradiated mice were found to migrate to the spleens. (Figure 3.) The CD34+ cells detected in the bone marrow of the mice were derived from the human CD34+ cells as indicated by the fact that they are class 2 positive, expressing HLA-DR alpha transcripts by reverse transcriptase dependent RNA PCR.
Lof(11-10) cells are class 1 positive, but class 2 negative.
Additional evidence that the PCR signals observed in the bone marrow are CD34+ cells derived comes from the lack of detection of SV40 T-antigen by DNA-PCR in these preparations.
Further characterization of state of differentiation of the W O 96/17627 PC~US95/15986 CD34+ cells within the bone marrow will be done by following the expression of various cell sur~ace receptors using reverse transcriptase dependent RNA PCR.
* * * * *
All publications mentioned hereinabove are hereby incorporated in their entirety by reference.
While the foregoing invention has been described in some detail for purposes of clarity and underst~n~;ns, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.
W O 96tl7627 PCTnUS9S/15986 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Mosca, Joseph D.
Gartner, Suzanne Kessler, Steven Hall, Eric Kaushal, Sumesh (ii) TITLE OF INVENTION: System For The Maintenance, Growth And Differentiation Of Human And Non-Human Primate Pluripotent Stem, Progenitor And Mature Bone Marrow Cells (iii) NUMBER OF SEQUENCES: 33 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Finnegan, Henderson, Farabow, Garrett ~ Dunner (B) STREET: 1300 I Street, N.W., Suite 700 (C) CITY: Washington (D) STATE: D.C.
(E) COUNTRY: USA
(F) ZIP: 20005 (v) COM~U1~K READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COM~U1~K: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version ~1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/352,957 (B) FILING DATE: 09-DEC-1994 (C) CLASSIFICATION:
(vii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Fordis, Jean B.
(B) REGISTRATION NUMBER: 32,984 (C) REFERENCE/DOCKET NUMBER: 04995.0010-00000 (viii) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (202) 408-4000 (B) TELEFAX: (202) 408-4400 W 096/17627 P ~ ~US95~IS9~6 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
- (A) LEN~j1~: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOhECUhE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) L~;N~1~: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
TGACTGA~AG TCTATGACTT CTTGG 25 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) hENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECUhE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
W O96/17627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) hENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
W O96/17627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
- (A) L~N~l~: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: singl e (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:s:
W O96/17627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~l~: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
GGGA~ACTGA CGACCCTCGG TC 22 (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2 5 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (~enomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
W O 96/17627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
(2) INFORM~TION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
W O96/17627 PCTrUS95/1~986 (2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
WO96117627 pcT~sss/lsss6 (2) INFORMATION FOR SEQ ID NO:l9:
(i) SEQUENCE CHARACTERISTICS:
(A) L~lH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l9:
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
(2) INFORMATION FOR SEQ ID NO:2l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
W O96117627 PCTrUS95/15986 (2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
t2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
GGAACCTGCA G~lllllGGT GCAGGAGGAC 30 (2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
W O96/17627 PCTrUS95115986 (2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
(2) INFORM~TION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) L~N~l~: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (~ STR~NDEDNESS: siP~gle (D) TOPOLOGY: linear tii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
~ CCTCCCTGTC TCTTTTATGC TTGTGATC 28
Claims (21)
1. A method of engrafting human or non-human primate stem cells in a mouse comprising the steps of:
i) irradiating the mouse with a lethal or non-lethal dose of radiation;
ii) administering to the irradiated mouse immortalized human or non-human primate bone marrow stromal cells; and iii) administering to the irradiated mouse purified human or non-human primate stem cells.
i) irradiating the mouse with a lethal or non-lethal dose of radiation;
ii) administering to the irradiated mouse immortalized human or non-human primate bone marrow stromal cells; and iii) administering to the irradiated mouse purified human or non-human primate stem cells.
2. The method according to claim 1, wherein the immortalized bone marrow stromal cells and the purified stem cells are administered simultaneously or sequentially.
3. The method according to claim 2, comprising first administering said immortalized bone marrow stromal cells, followed by administering said purified stem cells.
4. The method according to claim 3, wherein said purified stem cells are administered about 10 days after the immortalized bone marrow stromal cells are administered.
5. The method according to claim 4, wherein said purified stem cells are administered 2-7 days after the immortalized bone marrow stromal cells are administered.
6. The method according to claim 1, wherein the immortalized bone marrow stromal cells are administered by intraperitoneal injection.
7. The method according to claim 1, wherein the purified stem cells are administered by intravenous injection.
8. The method according to claim 1, wherein the purified stem cells are purified CD34+ stem cells.
9. The method according to claim 1, wherein the mouse is immunosuppressed.
10. The method according to claim 9, wherein the mouse is a SCID mouse.
11. The method according to claim 1, wherein the immortalized bone marrow stromal cells are transfected with SV40 large T-antigen.
12. The method according to claim 11, wherein the immortalized bone marrow stromal cells are Lof(11-10) cells.
13. A method of testing the effectiveness of a gene therapy protocol against a retrovirus comprising the steps of:
i) irradiating a first and a second mouse with a lethal or non-lethal dose of radiation;
ii) administering to the irradiated mice immortalized human or non-human primate bone marrow stromal cells which express cytokines supporting growth of CD34+ stem cells;
iii) introducing a proposed therapeutic gene segment into a first group of human CD34+ stem cells;
iv) purifying the cells from the first group of CD34+
stem cells expressing the gene segment;
v) introducing a control gene segment into a second group of human CD34+ stem cells;
vi) administering the purified cells from step (iv) to the first irradiated mouse and administering the cells from step (v) to the second irradiated mouse;
vii) challenging the first and the second irradiated mice with the retrovirus; and viii) comparing the survival of the human CD34+ stem cells from the first mouse and the second mouse.
i) irradiating a first and a second mouse with a lethal or non-lethal dose of radiation;
ii) administering to the irradiated mice immortalized human or non-human primate bone marrow stromal cells which express cytokines supporting growth of CD34+ stem cells;
iii) introducing a proposed therapeutic gene segment into a first group of human CD34+ stem cells;
iv) purifying the cells from the first group of CD34+
stem cells expressing the gene segment;
v) introducing a control gene segment into a second group of human CD34+ stem cells;
vi) administering the purified cells from step (iv) to the first irradiated mouse and administering the cells from step (v) to the second irradiated mouse;
vii) challenging the first and the second irradiated mice with the retrovirus; and viii) comparing the survival of the human CD34+ stem cells from the first mouse and the second mouse.
14. The method according to claim 13, wherein the retrovirus is HIV.
15. The method according to claim 13, wherein the first and the second mouse are SCID mice.
16. An animal model for the study of human hematopoiesis comprising a rodent into which human or non-human primate CD34+ stem cells have been engrafted in the present of immortalized human or non-human primate bone marrow stromal cells.
17. The animal model according to claim 16, wherein the rodent is a mouse.
18. The animal model according to claim 17, wherein the mouse is immunosuppressed.
19. The animal model according to claim 18, wherein the mouse is a SCID mouse.
20. The animal model according to claim 16, wherein the immortalized bone marrow stromal cells are transfected with SV40 large T-cell antigen.
21. The animal model according to claim 20, wherein the immortalized bone marrow stromal cells are Lof(11-10) cells.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35295794A | 1994-12-09 | 1994-12-09 | |
| US352,957 | 1994-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2207216A1 true CA2207216A1 (en) | 1996-06-13 |
Family
ID=23387167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002207216A Abandoned CA2207216A1 (en) | 1994-12-09 | 1995-12-08 | System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0796110A2 (en) |
| JP (1) | JPH10510702A (en) |
| AU (1) | AU4419396A (en) |
| CA (1) | CA2207216A1 (en) |
| WO (1) | WO1996017627A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6800480B1 (en) | 1997-10-23 | 2004-10-05 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| AU5403100A (en) * | 1999-06-08 | 2000-12-28 | Novartis Ag | Enforced expression of bcl-xl |
| US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
| IL154159A0 (en) | 2000-08-01 | 2003-07-31 | Yissum Res Dev Co | Directed differentiation of ebryonic cells |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
-
1995
- 1995-12-08 WO PCT/US1995/015986 patent/WO1996017627A2/en not_active Application Discontinuation
- 1995-12-08 CA CA002207216A patent/CA2207216A1/en not_active Abandoned
- 1995-12-08 AU AU44193/96A patent/AU4419396A/en not_active Abandoned
- 1995-12-08 JP JP8517803A patent/JPH10510702A/en not_active Expired - Lifetime
- 1995-12-08 EP EP95943042A patent/EP0796110A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU4419396A (en) | 1996-06-26 |
| WO1996017627A3 (en) | 1996-10-31 |
| EP0796110A2 (en) | 1997-09-24 |
| WO1996017627A2 (en) | 1996-06-13 |
| JPH10510702A (en) | 1998-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107922925B (en) | Method for natural killer cell expansion | |
| CN106536719B (en) | Generation of mesenchymal stromal cell pool of pooled mononuclear cells from multiple bone marrow donors | |
| JP2002516085A (en) | Compositions and uses that affect hematopoietic stem cell populations in mammals | |
| AU7219994A (en) | Yolk sac stem cells and their uses | |
| Brenner | Gene marking | |
| KR20220097985A (en) | Method of making CAR-T cells | |
| KR20210018437A (en) | Method for producing hematopoietic stem cells | |
| CN113660942A (en) | Chimeric cytokine receptors | |
| JP2007511219A5 (en) | ||
| US11299709B2 (en) | Pluripotent stem cell and T cell differentiated therefrom and application thereof | |
| CA2207216A1 (en) | System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells | |
| Valtieri et al. | Efficient transfer of selectable and membrane reporter genes in hematopoietic progenitor and stem cells purified from human peripheral blood | |
| Watts et al. | Hematopoietic stem cell expansion facilitates multilineage engraftment in a nonhuman primate cord blood transplantation model | |
| WO1996017627A9 (en) | System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells | |
| CN114402065A (en) | Low density cell culture | |
| Andrews et al. | Differential engraftment of genetically modified CD34+ and CD34− hematopoietic cell subsets in lethally irradiated baboons | |
| US5702702A (en) | Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer | |
| EP0697875B1 (en) | Use of modified tall-104 cells to treat cancer and viral diseases | |
| Watts et al. | Differential effects of HOXB4 and NUP98-HOXA10hd on hematopoietic repopulating cells in a nonhuman primate model | |
| JP2012507997A (en) | Cell, nucleic acid construct, cell containing said construct, and method of using said cell in the treatment of disease | |
| JP2010533486A (en) | Stem cell in vitro growth medium | |
| Ailles et al. | Retroviral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice | |
| JP2023504075A (en) | Method for obtaining CAR-NK cells | |
| Sellers et al. | The presence of the carboxy-terminal fragment of fibronectin allows maintenance of non-human primate long-term hematopoietic repopulating cells during extended ex vivo culture and transduction | |
| US5820856A (en) | Modified TALL-104 cells to treat cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |